Author

J. P. Ernest

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 1 Pharmacology & Toxicology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:mouse· 2 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Research Focus:host-pathogen & immune response· 1 Approach:statistical model· 1

Frequent Co-Authors

R. M. Savic· 2 shared A. A. Bauman· 1 shared A. Deitchman· 1 shared B. K. Podell· 1 shared C. Dide-Agossou· 1 shared E. Nuermberger· 1 shared F. Kaya· 1 shared G. T. Robertson· 1 shared

Activity by Year

2023-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 27 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersMicrobiology

R. M. Savic

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

MicrobiologybioRxivPreprintFeb 3, 2023

Lung microenvironments harbor Mycobacterium tuberculosis phenotypes with distinct treatment responses

N. D. Walter, J. P. Ernest, C. Dide-Agossou…·G. T. Robertson

The paper shows that Mycobacterium tuberculosis in different lung microenvironments have distinct phenotypes and treatment responses in a mouse model.

DOI 10.1101/2023.02.03.527062

mouseexperimental assay

𝕏 PostBluesky

Pharmacology & ToxicologybioRxivJan 18, 2023

Translational predictions of phase 2a first-in patient efficacy studies for antituberculosis drugs

R. M. Savic, J. J. N. Goh, J. P. Ernest…·E. Nuermberger

The paper predicts clinical efficacy of antituberculosis drugs using preclinical PKPD data and translational pharmacology models to reduce phase 2a trial costs and failures.

DOI 10.1183/13993003.00165-2023

mousestatistical model

𝕏 PostBluesky